[Features] NMN Just Got EU Safety Approval — What It Means (and What It Doesn’t)

On May 13, 2026, the European Food Safety Authority (EFSA) issued a positive safety opinion stating that up to 300 mg/day of NMN (β-nicotinamide mononucleotide) is safe for the general adult population. The longevity community erupted: “The EU has approved it!” “Dr. Sinclair was right!” But there is a crucial distinction here — “approved as safe” is not the same as “proven effective.” This piece separates those two claims and audits the actual NMN evidence at Levels 1–4.

Conclusion: Safety is Level 1. Efficacy is Level 2–3. Whether to take it depends on your goal.

[Level 1 (safety) / Level 2–3 (efficacy)] [Supplements] [Conditionally recommended]

EFSA’s May 2026 Positive Safety Opinion essentially establishes NMN safety at up to 300 mg/day as Level 1, based on multiple human RCTs and regulatory review. For efficacy, however, the picture is more nuanced: blood NAD+ elevation is Level 1 (clearly demonstrated), but effects on physical function, metabolism, sleep, and gait speed land at Level 2–3 with mixed evidence. Claims of “reversing aging” or “extending lifespan” remain at Level 4 (animal studies only) in humans.

📰 May 13, 2026: What EFSA Actually Approved

Let us start by getting the news itself accurate.

• Issuing body: European Food Safety Authority (EFSA) — the EU’s independent scientific agency for food safety
• What was issued: A Positive Safety Opinion concluding that β-NMN (filed by Shanghai Shangke Biotechnology / EffePharm of China) is safe for the general adult population (excluding pregnant and lactating women) at up to 300 mg/day
• Status: This is one step short of full “Novel Food” authorization. A Safety Opinion clears the scientific hurdle; the European Commission’s formal approval still takes several more months
• Separately: Uthever® NMN (US-based ChromaDex affiliate) has already secured Novel Food authorization through a different filing, becoming the first NMN ingredient legally sold across the EU

What EFSA actually “proved” is safety. It said nothing about efficacy. That is appropriate — establishing efficacy is not the role of a food safety regulator.

For context: the US FDA in 2022 declared NMN ineligible for sale as a “new dietary ingredient” because it was under drug development, creating a long gray zone. In 2025 that position was reversed and NMN became legally sellable again. The EU is now moving in the opposite direction — explicitly classifying it as a food supplement.

🧬 What Is NMN? (And What Does Dr. Sinclair Actually Claim?)

NMN (β-nicotinamide mononucleotide) is a form of vitamin B3 (niacin). In the body it converts to NAD+ (nicotinamide adenine dinucleotide), an essential coenzyme involved in mitochondrial ATP production, DNA repair, sirtuin (longevity-related enzyme) activation, and redox balance.

NAD+ declines with age — this is well established in both human and animal studies (by age 50, levels are roughly half those at age 20). Whether this decline causes aging or merely tracks it remains debated.

Harvard Medical School’s Professor David Sinclair (author of the bestseller Lifespan: Why We Age — and Why We Don’t Have To) proposes that taking NMN orally restores NAD+ to youthful levels, activates sirtuins, and extends healthspan. In laboratory mice, NMN supplementation has been linked to improvements in physical performance, insulin sensitivity, mitochondrial function, and even coat color.

Here is what matters. The dramatic effects seen in mice have not been reproduced in humans at the same magnitude. This does not mean the mouse studies were wrong — it means cross-species extrapolation always requires caution.

📊 Human Effect Sizes & Key Studies

Since 2020 there have been roughly 20 human RCTs (randomized controlled trials) on NMN. Here are the highlights, organized by evidence level.

NAD+ blood elevation (Level 1 — clearly demonstrated)

• Yoshino et al., Science 2021: 25 prediabetic women, 250 mg/day for 10 weeks. NAD+ metabolites rose significantly; muscle insulin sensitivity improved by 25% vs. placebo.
• Yamaguchi et al., Endocrine Journal 2024: Middle-aged Japanese men, 250 mg/day for 12 weeks. NAD+ in peripheral blood mononuclear cells rose significantly; no safety concerns observed.
• 2024 meta-analysis (Critical Reviews in Food Science and Nutrition): Pooled multiple RCTs. Concluded that NMN significantly increases blood NAD+ levels.

Physical function & gait speed (Level 2 — moderate)

• Igarashi et al., npj Aging 2022: 42 Japanese older adults, 250 mg/day for 12 weeks. Gait speed and grip strength improved significantly vs. placebo (+12%).
• Yi et al., GeroScience 2023: 80 adults, 300 vs. 600 mg/day for 60 days. SF-36 quality-of-life score improved in a dose-dependent manner.
• 2024 Cureus systematic review: Improvements in physical performance metrics are reproducible across multiple RCTs.

Metabolic markers — glucose and lipids (Level 2–3 — mixed)

• 2024 meta-analysis (PMC11557618): In adults, NMN at 250–2,000 mg/day did NOT significantly improve fasting glucose, HbA1c, or LDL/HDL cholesterol.
• Exception: In Yoshino 2021, muscle insulin sensitivity improved specifically in prediabetic women — but this was a narrow population.
• So the claim that “NMN improves metabolic markers in healthy adults” is not currently supported by the pooled evidence.

Sleep & mood (Level 3 — suggestive)

• Kim et al., 2024: Older adults, 250 mg/day for 12 weeks. Sleep quality (PSQI) improved significantly. Sample size was small.

Hair & beauty (Level 3 — single study)

• 2025 study: Women aged 40–50, 500 mg/day for 12 weeks. Anagen-phase hair density and hair diameter increased significantly. The cosmetics industry is paying close attention, but replication is needed.

Lifespan extension (Level 4 — animal-only)

• Multiple mouse studies report lifespan and healthspan extension. No human study has measured lifespan (it would take decades to run).
• When influencers assert “NMN extends your lifespan,” that is currently an over-extrapolation from animal data.

🔬 Mechanism: What NMN Is Actually Doing

Once ingested, NMN follows a known biochemical path:

1. Absorption: NMN is absorbed in the small intestine (via the Slc12a8 transporter).
2. Conversion: Inside cells, the NMNAT enzyme converts NMN to NAD+.
3. NAD+ roles:
   • ATP production in mitochondria
   • Cofactor for the DNA repair enzyme PARP
   • Activation of sirtuins (SIRT1–7)
   • Maintenance of cellular redox balance
4. Excretion: Excess NAD+ is degraded and excreted in urine.

The mechanism itself is well established. The debate is about effect size — how much do clinical outcomes actually improve in humans when NAD+ rises?

🆚 NMN vs. NR vs. Niacin — What’s the Difference?

NAD+ has several precursors. The supplement aisle confuses many people, so here is a clear comparison.

NMN is not uniquely magical. If your goal is to raise NAD+, NR is a reasonable alternative (often cheaper, with more accumulated clinical data), and even plain niacin or nicotinamide are options. NMN tends to win on two grounds: Dr. Sinclair’s brand and absence of flushing.

🎯 How to Start (If You Decide To)

If you decide to try NMN, here is a defensible protocol based on current evidence:

1. Dose: 250–500 mg/day. EFSA’s safe upper limit is 300 mg/day; effective doses in human RCTs span 250–600 mg/day. Higher doses (1,000 mg+) show no additional benefit and add cost.
2. Timing: morning. Sirtuins follow circadian rhythm; taking it during the active phase is theoretically preferable. (Strict head-to-head timing studies in humans are still limited.)
3. Form: powder or sublingual. “Liposomal” or “sustained-release” forms often cost more without strong added-benefit evidence.
4. Duration: at least 3 months. Most human RCTs run 12 weeks or longer before measuring change.
5. Measurement: blood NAD+ if possible. Some clinics and direct-to-consumer labs now offer this test (typically $80–200).

How to choose a product:

• Pick third-party tested brands (USP, NSF, Informed-Sport certification).
• NMN is unstable and ideally stored refrigerated. Cheap room-temperature stockpiles may already be partly degraded.
• “99%+ pure” claims without third-party testing are unverifiable.
• The EU’s Uthever® authorization confirms quality for that specific brand, not NMN in general.

⚠️ Cautions (Easily Misunderstood Points)

1. “Safe” is not the same as “effective”

EFSA cleared safety, not efficacy. The argument “EU approved it, so I should take it” does not follow. This is the same structure as “Vitamin C is safe — but safety alone doesn’t mean you should take a supplement.”

2. Not recommended during pregnancy or breastfeeding

EFSA explicitly excluded pregnant and lactating women from its Safety Opinion. Avoid NMN during these periods.

3. Cancer survivors and patients should consult their physician

NAD+ also fuels cancer cell metabolism, and some preclinical research suggests NAD+ precursors may accelerate tumor growth. If you are undergoing chemotherapy, radiation, or are in remission, talk to your oncologist before starting NMN.

4. “Dr. Sinclair takes it” is not evidence

Professor Sinclair has financial ties to NAD+ supplement companies (MetroBiotech and others), creating a conflict of interest. His personal regimen is a personal choice, not scientific data. This is not a criticism of Professor Sinclair — it is a general principle: do not substitute influencer choices for evidence.

5. NMN alone will not deliver anti-aging

If you have not yet implemented the Level 1 interventions (smoking cessation, exercise, sleep, Mediterranean diet, social connection), starting with NMN is a misplaced priority. Treat NMN as an add-on after the Level 1 stack is in place, not as a substitute.

6. Think about cost-effectiveness honestly

Before committing $30–60/month to NMN, ask whether that budget could deliver more health per dollar elsewhere: running shoes, a yearly physical, oily fish, nuts, olive oil, green tea, or simply earlier bedtimes (with the opportunity cost of less evening entertainment). For most people, those Level 1 interventions have larger expected effect sizes than NMN.

👥 Who Might Reasonably Try It / Who Should Not

Reasonable candidates for NMN:

• Adults 40+ who already practice the Level 1 interventions (exercise, diet, sleep)
• Those interested in maintaining physical function — gait speed, grip strength
• Those with budget to spend $30–60/month for 3–6 months as a personal experiment
• Those mentally prepared for “no measurable benefit, but at least it is safe”

Who should NOT take NMN:

• Pregnant or breastfeeding women
• Cancer survivors or patients under treatment (consult your physician first)
• Healthy adults under 30 (baseline NAD+ decline is minimal, expected benefit small)
• People expecting dramatic anti-aging effects (over-expectation leads to disappointment)
• People whose exercise, diet, and sleep are not yet in order (the priority is wrong)
• Anyone whose budget is already stretched (poor cost-effectiveness)

📝 Summary

• In May 2026, EFSA confirmed NMN at up to 300 mg/day as safe at Level 1. Efficacy is a separate question.
• In humans: NAD+ elevation is Level 1, physical function improvement is Level 2, metabolic improvement is Level 2–3 (mixed), lifespan extension is Level 4 (mice only).
• NR, niacin, and nicotinamide are also NAD+ precursors. NMN is not uniquely magical.
• Dr. Sinclair’s hypothesis deserves serious consideration as a hypothesis, but the evidence does not yet rise to “strongly recommended.”
• If taking NMN: 250–500 mg/day for at least 3 months, third-party tested, refrigerated.
• If your Level 1 stack (exercise, diet, sleep) isn’t in place yet, your dollars buy more health there first.

📚 References (peer-reviewed)

• EFSA Panel on Nutrition, Novel Foods and Food Allergens. Safety of beta-nicotinamide mononucleotide (β-NMN) as a novel food. EFSA Journal. 2026;24(5):10007.
• Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–1229.
• Igarashi M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood NAD+ levels and supports physical function in older men. npj Aging. 2022;8(1):5.
• Yamaguchi S, et al. Safety and efficacy of long-term nicotinamide mononucleotide supplementation in healthy middle-aged Japanese men. Endocrine Journal. 2024;71(2).
• Yi L, et al. The efficacy and safety of β-NMN supplementation in healthy middle-aged adults: a dose-dependent clinical trial. GeroScience. 2023;45(1):29–43.
• Wang X, et al. Effects of nicotinamide mononucleotide on glucose and lipid metabolism in adults: a systematic review and meta-analysis. Critical Reviews in Food Science and Nutrition. 2024.
• Cureus systematic review on NMN and physical performance, 2024.
• Dr. Sinclair DA, et al. Why NAD+ Declines during Aging. Cell Metabolism. 2016;23(6):965–966.
• NutraIngredients. EFSA issues positive safety opinion on EffePharm’s NMN. May 13, 2026.

⚠️ Disclaimer

• This article is written based on peer-reviewed scientific literature but is not a substitute for medical advice.
• Decisions about supplement use, especially with pre-existing conditions, should be made in consultation with a licensed physician or pharmacist.
• Pregnant and breastfeeding women, cancer survivors, and people undergoing chemotherapy should avoid NMN unless explicitly cleared by their physician.
• This article reflects evidence available as of May 2026. Future research may shift this assessment.

📚 Related Reading

• Evidence Framework — How We Evaluate the Evidence
• Independence Policy — Why evidage Has No Ads or Affiliates
• Foods in Focus Series
• Supplements